key: cord-0806015-eagq57d5 authors: Vanaerschot, Manu; Mann, Sabrina A.; Webber, James T.; Kamm, Jack; Bell, Sidney M.; Bell, John; Hong, Si Noon; Nguyen, Minh Phuong; Chan, Lienna Y.; Bhatt, Karan D.; Tan, Michelle; Detweiler, Angela M.; Espinosa, Alex; Wu, Wesley; Batson, Joshua; Dynerman, David; Wadford, Debra A.; Puschnik, Andreas S.; Neff, Norma; Ahyong, Vida; Miller, Steve; Ayscue, Patrick; Tato, Cristina M.; Paul, Simon; Kistler, Amy; DeRisi, Joseph L.; Crawford, Emily D. title: Identification of a polymorphism in the N gene of SARS-CoV-2 that adversely impacts detection by a widely-used RT-PCR assay date: 2020-08-26 journal: bioRxiv DOI: 10.1101/2020.08.25.265074 sha: 539af5053f2d200aed14a348726eb26699027a24 doc_id: 806015 cord_uid: eagq57d5 We identify a mutation in the N gene of SARS-CoV-2 that adversely affects annealing of a commonly used RT-PCR primer; epidemiologic evidence suggests the virus retains pathogenicity and competence for spread. This reinforces the importance of using multiple targets, preferably in at least 2 genes, for robust SARS-CoV-2 detection. Article Summary Line A SARS-CoV-2 variant that occurs worldwide and has spread in California significantly affects diagnostic sensitivity of an N gene assay, highlighting the need to employ multiple viral targets for detection. Standard diagnostic testing for SARS-CoV-2 infection involves examination of 34 respiratory specimens for the viral genome by RT-PCR. Typically, this is done with multiple 35 primer pairs targeting more than one viral gene. However, recent WHO guidelines (1) state that 36 "In areas where the COVID-19 virus is widely spread a simpler algorithm might be adopted in 37 which, for example, screening by RT-PCR of a single discriminatory target is considered 38 sufficient." Currently, 36 out of 175 FDA-approved Emergency Use Authorizations involve 39 assays that employ just a single target for RT-PCR (2). 40 Here we report the identification of a nucleotide change in an N gene primer sequence 41 that impairs annealing and amplification, resulting in increased C t values and decreased 42 diagnostic sensitivity. Our results indicate the potential hazard of relying on one target when 43 assaying for SARS-CoV-2, even in areas of high prevalence. The Study 45 Since April 7, 2020, the COVID-19 diagnostic laboratory at the Chan Zuckerberg Biohub 46 and the University of California San Francisco (CLIAHUB) has been receiving samples for no-47 cost testing from multiple counties in California. Our real-time RT-PCR protocol (3) employs N 48 gene (NIID_2019-nCov_N_F2/R2ver3/P2 (4)) and E gene (E_Sarbeco_F/R/P1 (5)) simplex 49 assays that have been used widely by other groups. In July 2020, we identified geospatial and 50 temporal clustering of 35 samples from Madera County, California that demonstrated poor N 51 gene assay performance relative to the E gene assay. We initiated an investigation to identify 52 possible causes. 53 Figure 1A shows the concordance of C t values for the two assays in the 3,957 positive 54 tests conducted in CLIAHUB during May 27 -August 7, 2020. For samples with positive E 55 and N gene results (n=3629), the N and E gene C t value difference (ΔC t (N-E)) was 0.40 ± 1.18 56 (mean ± standard deviation). We defined potential mutant sample set A as those with an For potential mutant sample set B, sequences were obtained for 14 out of 19 samples. Twelve of these carried the G29140T mutation. Importantly, the N gene RT-PCR did not detect 76 SARS-COV-2 in 5 of these 10 samples. Fortunately, these cases could still be recognized as 77 infected by use of the E gene assay. To further investigate the effect of the G29140T mutation on N gene PCR performance, Table 1 . RT-PCR data with the mutated primer is available in Appendix 131 Table 2 . Sequence data is available via GISAID; see Appendix Table 3 . Figure 1A . Table 2 . Raw data detailing the individual Δ Ct(N-E) data points depicted in Figure 1C . 208 Appendix Table 3 . Metadata of sequences depicted in Figure 2 . World Health Organization. Laboratory testing for coronavirus disease (COVID-19) in 139 suspected human cases. WHO Interim Guidance Rapid deployment of SARS-CoV-2 testing: the CLIAHUB. 143 Under review Development of 145 genetic diagnostic methods for novel coronavirus 2019 (nCoV-2019) in Japan Detection of 148 2019 novel coronavirus (2019-nCoV) by real-time PCR disease and diplomacy: GISAID's innovative 150 contribution to global health Architecture and self-assembly of the SARS-152 CoV-2 nucleocapsid protein Multiplex 156 PCR method for MinION and Illumina sequencing of Zika and other virus genomes 157 directly from clinical samples Minimap2: pairwise alignment for nucleotide sequences The Sequence 163 alignment/map (SAM) format and SAMtools An 165 amplicon-based sequencing framework for accurately measuring intrahost virus diversity 166 using PrimalSeq and iVar Nextstrain: 168 real-time tracking of pathogen evolution Group Leader Infectious Disease Initiative 499 Illinois St. 4th floor